Statin Therapy Among Bariatric Patients : The Impact on Metabolic Outcomes and Diabetes Status
Thieme. All rights reserved..
INTRODUCTION: Statin therapy is associated with an increased risk of developing diabetes. Among bariatric patients, the influence of this therapy on various metabolic outcomes, such as diabetes status and its remission, is largely unknown.
METHODS: This was a retrospective study of 1710 patients who underwent bariatric surgery at our hospital between January/2010 and June/2017. We compared patients with and without statin therapy at baseline, 12 and 24 months after surgery regarding statin use and its impact on several clinical and analytical parameters. Multiple linear regression was performed, adjusting differences for age, sex, surgery type, antidiabetic drugs at baseline, hypertension at baseline, LDL cholesterol ˃ 130 mg/dL, weight variation one year after surgery, and age of obesity onset.
RESULTS: The overall prevalence of statin use was 20.2% before, 13.6% 12 months after surgery, and 15.0% 24 months after surgery. There was a larger reduction in fasting glucose and HbA1c at 12 and 24 months after surgery among statin-treated patients, with the opposite trend for weight reduction and BMI. Statin-treated patients with diabetes had lower diabetes remission rates (45.3 vs 68.5%) 12 months after surgery, with the highest reduction in HbA1c (1.3±1.3 vs -1.1±1.2%; p=0.042), fasting glucose (-40.8±48.8 vs -30.9±41.6 mg/dL; p=0.028), and insulin (-21.7±28.2 vs -13.4±14.2 mIU/L; p=0.039). The proportion of new-onset cases of diabetes was equal between statin-treated vs non-treated individuals at 12 months (1.9%) and 24 months (1.0%) after surgery.
CONCLUSION: Bariatric surgery seems to lead to diabetes remission more frequently in patients not treated with statins. A larger reduction was observed in fasting glucose and HbA1c among statin-treated patients. Statin did not contribute to an increased proportion of new-onset diabetes after surgery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association - 130(2022), 8 vom: 06. Aug., Seite 539-545 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mendonça, Fernando M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 15.08.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1743-2335 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338511873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338511873 | ||
| 003 | DE-627 | ||
| 005 | 20231226000834.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-1743-2335 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338511873 | ||
| 035 | |a (NLM)35320845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mendonça, Fernando M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statin Therapy Among Bariatric Patients |b The Impact on Metabolic Outcomes and Diabetes Status |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.08.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a INTRODUCTION: Statin therapy is associated with an increased risk of developing diabetes. Among bariatric patients, the influence of this therapy on various metabolic outcomes, such as diabetes status and its remission, is largely unknown | ||
| 520 | |a METHODS: This was a retrospective study of 1710 patients who underwent bariatric surgery at our hospital between January/2010 and June/2017. We compared patients with and without statin therapy at baseline, 12 and 24 months after surgery regarding statin use and its impact on several clinical and analytical parameters. Multiple linear regression was performed, adjusting differences for age, sex, surgery type, antidiabetic drugs at baseline, hypertension at baseline, LDL cholesterol ˃ 130 mg/dL, weight variation one year after surgery, and age of obesity onset | ||
| 520 | |a RESULTS: The overall prevalence of statin use was 20.2% before, 13.6% 12 months after surgery, and 15.0% 24 months after surgery. There was a larger reduction in fasting glucose and HbA1c at 12 and 24 months after surgery among statin-treated patients, with the opposite trend for weight reduction and BMI. Statin-treated patients with diabetes had lower diabetes remission rates (45.3 vs 68.5%) 12 months after surgery, with the highest reduction in HbA1c (1.3±1.3 vs -1.1±1.2%; p=0.042), fasting glucose (-40.8±48.8 vs -30.9±41.6 mg/dL; p=0.028), and insulin (-21.7±28.2 vs -13.4±14.2 mIU/L; p=0.039). The proportion of new-onset cases of diabetes was equal between statin-treated vs non-treated individuals at 12 months (1.9%) and 24 months (1.0%) after surgery | ||
| 520 | |a CONCLUSION: Bariatric surgery seems to lead to diabetes remission more frequently in patients not treated with statins. A larger reduction was observed in fasting glucose and HbA1c among statin-treated patients. Statin did not contribute to an increased proportion of new-onset diabetes after surgery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Silva, Maria M |e verfasserin |4 aut | |
| 700 | 1 | |a Borges-Canha, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Neves, João S |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Cláudia |e verfasserin |4 aut | |
| 700 | 1 | |a Cabral, Pedro M |e verfasserin |4 aut | |
| 700 | 1 | |a Guerreiro, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Lourenço, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Meira, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Maria J |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Pedro, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Varela, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Souto, Selma |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Freitas, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Group, Crio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association |d 1996 |g 130(2022), 8 vom: 06. Aug., Seite 539-545 |w (DE-627)NLM075292904 |x 1439-3646 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2022 |g number:8 |g day:06 |g month:08 |g pages:539-545 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1743-2335 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2022 |e 8 |b 06 |c 08 |h 539-545 | ||